Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Convertible Debt: 2016-2019

Historic Convertible Debt for Amicus Therapeutics (FOLD) over the last 4 years, with Dec 2019 value amounting to $2.1 million.

  • Amicus Therapeutics' Convertible Debt rose 6.43% to $2.2 million in Q2 2020 from the same period last year, while for Jun 2020 it was $2.2 million, marking a year-over-year increase of 6.43%. This contributed to the annual value of $2.1 million for FY2019, which is 98.78% down from last year.
  • Amicus Therapeutics' Convertible Debt amounted to $2.1 million in FY2019, which was down 98.78% from $175.0 million recorded in FY2018.
  • Amicus Therapeutics' 5-year Convertible Debt high stood at $175.0 million for FY2018, and its period low was $2.1 million during FY2019.
  • In the last 3 years, Amicus Therapeutics' Convertible Debt had a median value of $164.2 million in 2017 and averaged $113.8 million.
  • Per our database at Business Quant, Amicus Therapeutics' Convertible Debt climbed by 6.60% in 2018 and then slumped by 98.78% in 2019.
  • Over the past 4 years, Amicus Therapeutics' Convertible Debt (Yearly) stood at $154.5 million in 2016, then rose by 6.28% to $164.2 million in 2017, then increased by 6.60% to $175.0 million in 2018, then slumped by 98.78% to $2.1 million in 2019.